- Home
- ADTN vs BCYC Comparison
ADTN vs BCYC Comparison
Compare ADTN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTN
- BCYC
- Stock Information
- Founded
- ADTN 1985
- BCYC 2009
- Country
- ADTN United States
- BCYC United Kingdom
- Employees
- ADTN N/A
- BCYC N/A
- Industry
- ADTN Telecommunications Equipment
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ADTN Telecommunications
- BCYC Health Care
- Exchange
- ADTN Nasdaq
- BCYC Nasdaq
- Market Cap
- ADTN 616.5M
- BCYC 581.7M
- IPO Year
- ADTN 1994
- BCYC 2019
- Fundamental
- Price
- ADTN $7.71
- BCYC $8.34
- Analyst Decision
- ADTN Strong Buy
- BCYC Buy
- Analyst Count
- ADTN 4
- BCYC 10
- Target Price
- ADTN $12.00
- BCYC $25.00
- AVG Volume (30 Days)
- ADTN 840.2K
- BCYC 401.9K
- Earning Date
- ADTN 05-07-2025
- BCYC 05-01-2025
- Dividend Yield
- ADTN N/A
- BCYC N/A
- EPS Growth
- ADTN N/A
- BCYC N/A
- EPS
- ADTN N/A
- BCYC N/A
- Revenue
- ADTN $944,291,000.00
- BCYC $25,722,000.00
- Revenue This Year
- ADTN $14.44
- BCYC N/A
- Revenue Next Year
- ADTN $9.66
- BCYC $0.27
- P/E Ratio
- ADTN N/A
- BCYC N/A
- Revenue Growth
- ADTN N/A
- BCYC N/A
- 52 Week Low
- ADTN $4.34
- BCYC $6.10
- 52 Week High
- ADTN $12.44
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- ADTN 44.36
- BCYC 49.88
- Support Level
- ADTN $7.49
- BCYC $7.95
- Resistance Level
- ADTN $8.26
- BCYC $9.55
- Average True Range (ATR)
- ADTN 0.32
- BCYC 0.72
- MACD
- ADTN 0.08
- BCYC 0.05
- Stochastic Oscillator
- ADTN 45.00
- BCYC 43.98
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.